Andreas Muehler

IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro

Friedrich Hahn, Christina Wangen, Sigrun Häge et al. · Viruses · 2020 · 66 citations · Full text

Medicine, Infectious Diseases, Pharmacology +16

Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis

Andreas Muehler, Evelyn Peelen, Hella Kohlhof et al. · Multiple Sclerosis and Related Disorders · 2020 · 64 citations

Medicine, Pharmacology, Pharmacotherapy +14

The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study

Andreas Muehler, Hella Kohlhof, Manfred Groeppel et al. · Drugs in R&D · 2019 · 29 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects

Andreas Muehler, Hella Kohlhof, Manfred Groeppel et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2020 · 27 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

A double‐blind, randomized, placebo‐controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing‐remitting multiple sclerosis

Robert J. Fox, Heinz Wiendl, Christian Wolf et al. · Annals of Clinical and Translational Neurology · 2022 · 23 citations · Full text

Medicine, Neurology, Pharmacology +14